4 Undervalued Pharmaceutical Stocks Trading Below Fair Value

India's pharmaceutical industry combines domestic branded formulations with large scale generic drug exports to regulated markets like the United States, making earnings sensitive to pricing pressure, regulatory approvals and currency movements. Not every stock in the space trades at the same multiple. A screen of listed pharmaceutical stocks against the sector's average price to earnings ratio surfaces four names still priced below that benchmark.

Lupin, Zydus Lifesciences, Aurobindo Pharma and Cipla all currently trade below the broader pharmaceutical industry PE, despite posting positive return on equity. This piece breaks down why each stock screens as undervalued, what the underlying financials show, and the risks that come with owning pharmaceutical manufacturers.

Click Here – Get Free Investment Predictions

Why These Pharmaceutical Stocks Screen as Undervalued

The pharmaceutical industry currently carries an average price to earnings ratio of close to 37.4 times trailing earnings for companies in this generic and branded formulations classification. A stock trading meaningfully below that average, while still posting positive return on equity, is a reasonable starting point for a relative valuation screen.

All four companies below clear that bar, with Lupin standing out for combining the widest discount with the strongest return on equity, a combination not always available among pharmaceutical stocks priced at a discount to the sector multiple.

The table below lists these four companies alongside their current price, valuation multiple and return ratios.

Company	NSE Ticker	CMP (Rs)	PE Ratio	Sector PE	ROE	Market Cap (Rs Cr)
Lupin	LUPIN	2,173.70	18.05	37.38	23.76%	1,00,189
Zydus Lifesciences	ZYDUSLIFE	1,178.10	24.93	37.38	18.59%	1,14,508
Aurobindo Pharma	AUROPHARMA	1,612.40	25.15	37.38	9.25%	93,326
Cipla	CIPLA	1,407.20	33.90	37.38	11.27%	1,13,778

Lupin: Widest Discount, Highest ROE

Lupin manufactures generic and branded formulations across cardiovascular, diabetes and respiratory therapeutic segments, with a significant presence in the United States market. The stock trades at a price to earnings ratio of 18.05, less than half the sector average of 37.38, at a current price of around Rs 2,174.

Return on equity of 23.76 percent is the highest of the four pharmaceutical stocks in this list, supported by a debt to equity ratio of 0.29. On an EPS of Rs 121.40 and book value of Rs 490.96, the price to book multiple works out to 4.46.

Zydus Lifesciences: Strong ROE, Diversified Portfolio

Zydus Lifesciences produces generic formulations, active pharmaceutical ingredients and consumer wellness products across domestic and international markets. Its price to earnings ratio of 24.93 sits below the sector average of 37.38, at a current share price of around Rs 1,178.

Return on equity of 18.59 percent is the second highest of the group, and the debt to equity ratio of 0.46 is the highest among these four names. On an EPS of Rs 46.04 and book value of Rs 271.78, the price to book multiple works out to 4.22.

Aurobindo Pharma: Large Scale, Modest ROE

Aurobindo Pharma is one of India's largest generic drug manufacturers by volume, with a broad portfolio spanning antibiotics, antiretrovirals and other formulations. The stock trades at 25.15 times trailing earnings, below the sector average of 37.38, at a current price of around Rs 1,612.

Return on equity of 9.25 percent is the most modest of the four pharmaceutical stocks, though the debt to equity ratio of 0.21 remains low. On an EPS of Rs 64.49 and book value of Rs 658.53, the price to book multiple of 2.46 is the lowest among these four names.

Cipla: Largest Brand, Narrowest Discount

Cipla is a well established pharmaceutical company with a strong domestic branded formulations business alongside respiratory and generic drug exports. The stock trades at a price to earnings ratio of 33.90, the narrowest discount to the sector average of 37.38 among these four pharmaceutical stocks, at a current price of around Rs 1,407.

Return on equity of 11.27 percent is modest relative to Lupin and Zydus Lifesciences, and the debt to equity ratio of 0.02 is the lowest of the group, close to debt free. On an EPS of Rs 41.54 and book value of Rs 426.22, the price to book multiple works out to 3.30.

Valuation Snapshot: PE, PB and Dividend Yield

Beyond the headline price to earnings ratio, book value multiples and dividend yield round out the valuation picture for these four companies. Cipla stands out for its near debt free balance sheet despite trading closest to the sector average PE.

Company	Price to Book	Book Value (Rs)	Dividend Yield	Debt to Equity
Lupin	4.46	490.96	0.82%	0.29
Zydus Lifesciences	4.22	271.78	0.09%	0.46
Aurobindo Pharma	2.46	658.53	0.25%	0.21
Cipla	3.30	426.22	0.92%	0.02

Aurobindo Pharma trades at the lowest price to book multiple of the four, consistent with its more modest return on equity, while Cipla pays the highest dividend yield of the group alongside its minimal leverage.

Check Live PE, PB and ROE Data on the Univest Screener

Risks to Consider Before Buying These Pharmaceutical Stocks

A discount to the sector average price to earnings ratio does not remove company specific risk for pharmaceutical stocks exposed to regulatory and pricing factors.

US Generic Pricing Pressure

Intense price erosion in the US generic drug market has weighed on margins across the industry, and continued pricing pressure remains a key swing factor for export dependent companies.

Regulatory and USFDA Inspection Risk

Manufacturing facilities are subject to periodic inspections by regulators including the USFDA, and adverse observations or warning letters can disrupt production and delay new product approvals.

Currency Exposure

A significant share of revenue for these companies comes from exports, making earnings sensitive to fluctuations in the US dollar and other foreign currencies.

R&D and Patent Litigation Costs

Developing complex generics and biosimilars requires sustained research investment, and patent litigation with originator companies can add both cost and timeline uncertainty to new launches.

How to Track These Pharmaceutical Stocks

Investors evaluating these four names should track quarterly US generic pricing trends, new product approvals, and how the sector average PE moves relative to each company's own multiple over time, rather than relying on the valuation gap in isolation among pharmaceutical stocks. Comparing these numbers regularly is the most reliable way to judge whether the discount to fair value remains intact or has already closed.

Download the Univest iOS App or Univest Android App to track Lupin, Zydus Lifesciences, Aurobindo Pharma and Cipla share prices live and set price alerts.

Conclusion

Lupin, Zydus Lifesciences, Aurobindo Pharma and Cipla are the four pharmaceutical stocks currently trading below the sector's average price to earnings ratio of close to 37.4 times, while all four post positive return on equity. That combination makes them worth a closer look for investors who already want exposure to India's generic and branded formulations theme, though US pricing pressure and regulatory risk mean position sizing and diversification still matter when adding these names to a portfolio.

FAQs on Undervalued Pharmaceutical Stocks

Which pharmaceutical stocks are trading below the sector average PE?

Ans. Lupin, Zydus Lifesciences, Aurobindo Pharma and Cipla are currently trading below the pharmaceutical sector's average price to earnings ratio of close to 37.4 times, based on live NSE and BSE pricing.

Is Lupin undervalued compared to its sector?

Ans. Lupin trades at a price to earnings ratio of 18.05, less than half the sector average of 37.38, while delivering a return on equity of 23.76 percent, the highest among these four pharmaceutical stocks.

Why does Cipla trade closer to its sector average PE?

Ans. Cipla trades at 33.90 times earnings, the narrowest discount to the sector average of 37.38 among these four names, reflecting its more modest return on equity of 11.27 percent relative to Lupin and Zydus Lifesciences.

What is the market capitalisation of Zydus Lifesciences?

Ans. Zydus Lifesciences has a market capitalisation of around Rs 1,14,508 crore, with a price to earnings ratio of 24.93 against the sector average of 37.38.

Which of these pharmaceutical stocks carries the lowest debt?

Ans. Cipla carries the lowest debt to equity ratio of the four at 0.02, close to debt free, while Zydus Lifesciences runs the highest at 0.46.

What are the main risks in undervalued pharmaceutical stocks?

Ans. The main risks include pricing pressure in the US generic drug market, regulatory and USFDA inspection risk, currency exposure from export revenue, and the cost and timeline uncertainty of research and patent litigation.

Is a low PE enough reason to buy a pharmaceutical stock?

Ans. A price to earnings ratio below the sector average is a useful starting screen for pharmaceutical stocks but not a standalone buy signal. Investors should also review product pipeline strength, regulatory standing and export market exposure before investing.